D-0998-2017 Class III Terminated

Recalled by Valeant Pharmaceuticals North America LLC — Bridgewater, NJ

FDA drug recall D-0998-2017 was initiated by Valeant Pharmaceuticals North America LLC on Jun 28, 2017 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Package Insert - Obagi-C Rx System C-Therapy Night Cream is being recalled due to incomplete packaging/labeling. The bottle is missing the product insert and outer… The recall status is terminated (terminated Jan 16, 2018). Affected quantity: 844 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 26, 2017
Initiation Date
Jun 28, 2017
Termination Date
Jan 16, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
844 bottles

Product description

Obagi-C Rx System C-Therapy Night Cream, Net wt. 2 oz. (57g) bottle, Rx only, Distributed by OMP, Inc., Long Beach, CA Made in USA, NDC 62032-222-02

Reason for recall

Labeling: Incorrect or Missing Package Insert - Obagi-C Rx System C-Therapy Night Cream is being recalled due to incomplete packaging/labeling. The bottle is missing the product insert and outer carton which contain the complete instruction for use and safety information.

Distribution pattern

U.S. Nationwide

Code information

Lot #: 2578400, 0Exp 8/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0998-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0998-2017. Report a data issue: hello@regdatalab.com.